ARTICLE | Clinical News
Amgen's anakinra slows joint damage in RA patients
October 30, 2000 8:00 AM UTC
AMGN announced additional data from a Phase II 472-patient trial of anakinra, an interleukin-1 receptor antagonist to treat rheumatoid arthritis (RA) (see BioCentury July 10). Patients receiving the ...